Peptide Libraray

Na05

General Information

DRACP ID DRACP01780

Peptide Name Na05

Sequence RRNDLRSXFLTLRDXVP

Sequence Length 17

UniProt ID Not available

PubChem CID Not available

Origin Synthetics

Type Synthetic peptide

Classification

Active ACP

Activity Information

Cell Line	Disease	Cancer Classified	Activity	Assay	Testing Time	Literature
RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients	Glioblastoma	Blastoma	EC50≈10 μM	CYTELL assay	72-96 h	Patent

Hemolytic Activity Not available

Normal (non-cancerous) Cytotoxicity Not available

Target Not available

Affinity Not available

Mechanism Not available

Nature Anticancer; Antitumor

Structure Information

PDB ID Not available

Predicted Structure Not available

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Free

Other Modification X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na07) links both Xs radicals in each sequence

Chiral L

Physicochemical Information

Formula C80H132N28O21

Absent amino acids ACEGHIKMQWY

Common amino acids R

Mass 232766

Pl 12.02

Basic residues 4

Acidic residues 2

Hydrophobic residues 5

Net charge 2

Boman Index -6795

Hydrophobicity -77.65

Aliphatic Index 85.88

Half Life
/

Extinction Coefficient cystines 0

Absorbance 280nm 0

Polar residues 3

Amino acid distribution

Literature Information

Literature 1

Pubmed ID Not available

Title Not available

Doi Not available

Year Not available

Patent

Patent ID US2020/0157150A1

Patent Title Anticancer Peptides

Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017

Other Published ID AU2018311129A1 CA3071601A1 CN111436200A EP3661947A1 JP2020529429A KR20200032730A WO2019025432A1